Trials / Completed
CompletedNCT00055562
Study to Compare the Efficacy and Safety of Two CC-5013 Dose Regimens in Subjects With Metastatic Malignant Melanoma
Multicenter, Randomized, Controlled, Double-Blind, Parallel-Group Study to Compare the Efficacy and Safety of Two CC-5013 Dose Regimens in Subjects With Metastatic Malignant Melanoma Whose Disease Has Progressed on Treatment With DTIC, IL-2 or IFN Based Therapy
- Status
- Completed
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 274 (planned)
- Sponsor
- Celgene Corporation · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Subjects are randomized to one of two treatment arms. All subjects are screened for eligibility within 28 days prior to randomization. The study consists of a treatment phase and a follow-up phase. Subjects will be treated in repeating 4 week cycles.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CC 5013 |
Timeline
- Start date
- 2003-01-01
- Completion
- 2004-12-01
- First posted
- 2003-03-06
- Last updated
- 2005-06-24
Locations
31 sites across 2 countries: United States, Canada
Source: ClinicalTrials.gov record NCT00055562. Inclusion in this directory is not an endorsement.